

# **Morning Meeting Notes**

# QuickNotes

**Morning Call** 

# **US EQUITIES RESEARCH**

# **Rating Changes**

Ameren Corp | NEUTRAL | AEE US | Mkt Cap:USD19,371mn | Julien Dumoulin-Smith

Downgrade to Neutral: Lower capital coming post Illinois decision

- Downgrade to Neutral following IL rate case outcomes for gas and electric; future capex a key question in IL
- See EPS trending to around 5% growth, well below target; offsets potentially to come include O&M cuts, less equity
- Valuation is not expensive at present, in-line with group on 2026 estimates, move to Neutral and \$77 PO

**ING** | NEUTRAL | ING US | Mkt Cap:USD55,103mn | Tarik El Mejjad Needs more than one string to its bow - downgrade to Neutral

- We downgrade ING to Neutral, cut our PO to EUR16.4 from EUR20.1. We cut 2024/25E net profit by 12%/16% from 4%/5% lower NII
- Cons NII too high, still assuming high for longer rates. Our analysis shows that ING replicating portfolio becomes a headwind
- ING equity story now rests on excess capital return, priced-in. Gap between current SBB ending soon and next SBB is a risk

State Street | UNDERPERFORM | STT US | Mkt Cap:USD23,854mn | Ebrahim Poonawala

2024 Year Ahead: Top ten questions asked (and answered)

- Bank stock rally should have legs given potential for positive inflection in EPS revisions in 2H24, discounted valuations
- Hard landing the biggest risk to stocks with credit normalization priced-in, investors likely to look past margin pressures
- Relative valuation vs. the S&P, attractive dividend yields, potential for regulatory relief, US elections...all positives

### 04 January 2024

Equity United States

Investor Support

#### Today's Events: Economic Indicators

N/A

Table of Contents	
US EQUITIES RESEARCH	1
Rating Changes	1
PO Raised	2
Significant EPS Change	3
Buy Reiterations	4
Macro & Strategy	6

QuickNotes is a list of today's Global Research activities. Please use the links to read the full Research report before making investment decisions. The reports also contain important disclosures.

# Truist Financial | BUY | TFC US | Mkt Cap:USD28,490mn | Ebrahim Poonawala

## 2024 Year Ahead: Top ten questions asked (and answered)

- Bank stock rally should have legs given potential for positive inflection in EPS revisions in 2H24, discounted valuations
- Hard landing the biggest risk to stocks with credit normalization priced-in, investors likely to look past margin pressures
- Relative valuation vs. the S&P, attractive dividend yields, potential for regulatory relief, US elections...all positives

# WEC Energy Group Inc | UNDERPERFORM | WEC US | Mkt Cap:USD27,320mn | Julien Dumoulin-Smith Downgrade to Underperform: Clouds to low-vol, dependable growth story

- Downgrade WEC from Neutral to Underperform; no longer a premium due to 1) no longer reliably exceeding financial guidance,
- 2) Top mgmt turnover amidst a tumultuous moment. Illinois risks linger w/ capex review (B/S risk) & gas legislation into '24.
- 3) Parent refi risks still driving 6-12c EPS downside on our ests by 2026; PO to \$78, downgrade to Underperform

## PO Raised

## Fluence Energy | BUY | FLNC US | Mkt Cap:USD3,844mn | Julien Dumoulin-Smith

New year looks good (and so does '25) - Reiterate Buy

- Robust backdrop for battery storage deployments remains key tailwind for FLNC supporting multi-year annual growth >35%
- Key to watch will be margin progression as legacy contracts roll off success in driving repeat business critical, too
- Updating estimates heading into '24, raising PO to \$28 reit. Buy. Volumes bias higher but watch Domestic Contents margins.

# JP Morgan Chase | BUY | JPM US | Mkt Cap:USD495,316mn | Ebrahim Poonawala

### 2024 Year Ahead: Top ten questions asked (and answered)

- Bank stock rally should have legs given potential for positive inflection in EPS revisions in 2H24, discounted valuations
- Hard landing the biggest risk to stocks with credit normalization priced-in, investors likely to look past margin pressures
- Relative valuation vs. the S&P, attractive dividend yields, potential for regulatory relief, US elections...all positives



# Morgan Stanley | BUY | MS US | Mkt Cap:USD162,865mn | Ebrahim Poonawala

## 2024 Year Ahead: Top ten questions asked (and answered)

- Bank stock rally should have legs given potential for positive inflection in EPS revisions in 2H24, discounted valuations
- Hard landing the biggest risk to stocks with credit normalization priced-in, investors likely to look past margin pressures
- Relative valuation vs. the S&P, attractive dividend yields, potential for regulatory relief, US elections...all positives

# **ZIM** | UNDERPERFORM | ZIM US | Mkt Cap:USD1,474mn | Muneeba Kayani Red Sea disruption - raising 2024E EBITDA estimates

- Red Sea disruption has resulted in a spike in spot rates; rates outlook is skewed to the upside at least for the next month.
- We now forecast a lower decline of -5% in ZIM's average freight rate in 2024E driving our EBITDA estimate to \$0.8bn.
- We reiterate Underperform on 7% downside potential

# Significant EPS Change

# Rogers | BUY | RCI US | Mkt Cap:USD24,014mn | David Barden 4Q23 Preview: Delivering merger synergies and leading wireless subscriber growth

- Rogers is our Top Pick among Canadian telecom stocks. It is on track to deliver on its synergy and leverage targets.
- Wireless subscriber activity was elevated during 4Q which will result in higher churn.
- Broadband subscriber competition remains intense but synergies will drive improved cable margins.

# TELUS Corp | BUY | TU US | Mkt Cap:USD26,226mn | David Barden 4Q23 Preview: Focus shifting from 2H23 competitive moves to '24 outlook

- We update our estimates ahead of 4Q23 results expected in early February.
- Underlying market demand remains healthy in a seasonally competitive 4Q that pressured ARPU and elevated churn.
- We expect TELUS to guide to 2024 adj. EBITDA growth of 6% and FCF of approximately \$2.3bn.



# **Buy Reiterations**

## **Health Care**

# Option Care Health | BUY | OPCH US | Mkt Cap:USD6,086mn | Joanna Gajuk Awaiting 2024 guide - we expect conservative start, upside from deals

- Next catalyst for OPCH is the 2024 guidance could be out in Jan. We expect the guide to bracket consensus.
- Historically OPCH beat its original guide by 9% on average. Expect similar scenario

   upside could come from deals.
- 2024 consensus EBITDA assumes core growth of 12% y/y, conservative given 14% core gr. in 2023 despite headwinds. Reit Buy.

# BioMarin | BUY | BMRN US | Mkt Cap:USD18,193mn | Geoff Meacham US Biopharmaceuticals

- Given the current macro backdrop, we remain optimistic on the performance of Biopharma in 2024
- Valuation looks reasonable across Pharma/ Biotech; resurgence of M&A and major innovation should keep investors engaged
- For more detailed stock-specific thoughts, please join us TODAY at 10:30 am ET for our Biopharma outlook call

# CVS Health | BUY | CVS US | Mkt Cap:USD104,084mn | Allen Lutz CVS updates formulary to drive greater biosimilar adoption

- Today, CVS announced a formulary update to remove Humira from commercial formularies and cover Humira biosimilars
- CVS also announced AbbVie has entered into an agreement to supply Cordavis with a committed volume of co-branded Humira
- Biosimilars represent another way for CVS to drive down costs and capture additional economics

### Information Technology

# Nutanix | BUY | NTNX US | Mkt Cap:USD10,759mn | Wamsi Mohan Changes to pricing at VMW could end up positive for NTNX

- Changes to pricing, bundling and shift to subscription at competitor VMW could be a net positive for Nutanix
- Broadcom's upcoming termination of VMW channel program and proposed selective transition to a new program creates disruption
- Reiterate Buy as we see NTNX benefiting from the re-evaluation of VMW customer environments



# **CrowdStrike** | BUY | CRWD US | Mkt Cap:USD55,239mn | Tal Liani Cyber Security

- We believe cybersecurity is still the place to be, but we favor the laggards after a year of strong performing cyber stocks
- Our top picks for 2024 are Fortinet & CyberArk; we maintain Buy on CrowdStrike
   & Zscaler, yet see some valuation risk in 2024
- We flag Underperform-rated Okta as having the greatest risk over the NTM, given valuation and fundamental challenges

# <u>Synopsys</u> | BUY | SNPS US | Mkt Cap:USD74,838mn | Vivek Arya Potential Ansys deal: long-term strategic, but with high regulatory, accretion hurdles

- We analyze range of scenarios of possible SNPS-ANSS combination, see 1%-5% CY26E EPS accretion at midpoint
- We see potential long-term synergies between SNPS-ANSS though highlight risks around execution, regulatory hurdles (US/China)
- Maintain Buy on SNPS on organic merits related rising chip complexity (especially in field of Al)

# Fortinet | BUY | FTNT US | Mkt Cap:USD48,499mn | Tal Liani Cyber Security

- We believe cybersecurity is still the place to be, but we favor the laggards after a year of strong performing cyber stocks
- Our top picks for 2024 are Fortinet & CyberArk; we maintain Buy on CrowdStrike
   & Zscaler, yet see some valuation risk in 2024
- We flag Underperform-rated Okta as having the greatest risk over the NTM, given valuation and fundamental challenges

#### **Materials**

# Newmont | BUY | NEM US | Mkt Cap:USD46,100mn | Lawson Winder Site visit to Newmont Australia: with a focus on the Tanami and Boddington mines

- In December we attended site visits to Newmont's (NEM's) Boddington and Tanami mines in Australia.
- The mines account for 10% and 6% of our total net asset value (NAV) for NEM, respectively.
- The assets showed significant potential for mine life extension and/or expansion.
   Maintain Buy rating.



# Macro & Strategy

## **GEMs FI Strategy Watch** | Jane Brauer

# 2024 EXD sovereign supply forecasts - just 1% inflows needed to cover net issuance

- Looking for bonds? We forecast gross sovereign external debt of \$143bn in '24.
- Net of amortizations, we expect net issuance of \$71bn. See table of country forecasts inside.
- Good news: We assume the coupons are reinvested in EM Debt, so just 1% inflows needed to support this issuance in '24.

## Mexico Watch | Carlos Capistran

## What you missed while on holiday

- We compiled the main releases since December 18 so you can catch up on Mexico's latest.
- The domestic economy was strong at the end of 2023, in part supported by government expenditure, which pressures inflation.
- The government issued US\$7.5bn and increased excise taxes by more than Banxico's 3% inflation target in January.

## **BofA on USA** | US Economics

## Weekly spending update through Dec 30

- Total card spending per HH was up 1.0% y/y in the week ending Dec 30, according to BAC aggregated credit and debit card data.
- Spending on holiday items fell 1.3% y/y in the week ending Dec 30. See footnote to Exhibit 2 for a holiday items definition.
- However, in the five weeks since Thanksgiving, spending on holiday items was up 0.3% compared to the same period last year.

#### Global Fund Performance Monitor | Nigel Tupper

### Value dominance faded

- 2023 proved difficult for Active funds with only 37% outperforming with a median return of -1.61% versus benchmark.
- Value funds were the best performers in 2023 with 55% outperforming by a median 0.46%. Only 36% of Growth funds outperformed.
- The dominance of Value faded as bond yields fell. Growth outperformed benchmark in December while Value underperformed.

### FX Technical Advantage | Paul Ciana

### Euro's golden cross favors mid-January bounce back

- Euro scored its 17th golden cross signal on Jan 3. History is short-term bullish 6-13 trading days later (up 69-81% of time.)
- But med-term risks to higher euro / lower \$ views in Q1/H1 remain. Euro's weekly chart risk is still a head & shoulders top.
- We close a tactical long on USDKRW 1m NDF, we were stopped on short MXNCLP and we closed short GBPAUD and EURNOK.



## **US Mutual Fund Performance Update** | Savita Subramanian

## A tough year for Core & Growth, but Value funds continued to shine

- 38% of large cap active funds outperformed in 2023, the worst hit rate since COVID but in line with the historical average.
- Value funds outperformed while Core/Growth lagged. SMID funds also struggled, with only 22% of mid cap funds outperforming.
- Expect a better backdrop for actives in 2024. Breadth should improve from a record low; idiosyncratic risk has increased.

### **Growth 10 & Value 10** | Savita Subramanian

## Screen for January 2024

- Growth 10: No changes. Full screen: AMZN, CMG, WBD, GOOGL, LLY, META, NFLX, PODD, TMUS, URI
- Value 10: No changes. Full screen: ACGL, AFL, GEN, DRI, GM, HD, NUE, RL, TMUS, URI
- The screens are quantitatively generated and are based on our BofA vs. Consensus Model and three other screening criteria.



# **Disclosures**

# **Important Disclosures**

FUNDAMENTAL EQUITY OPINION KEY: Opinions include a Volatility Risk Rating, an Investment Rating and an Income Rating. VOLATILITY RISK RATINGS, indicators of potential price fluctuation, are: A - Low, B - Medium and C - High. INVESTMENT RATINGS reflect the analyst's assessment of both a stock's absolute total return potential as well as its attractiveness for investment relative to other stocks within its Coverage Cluster (defined below). Our investment ratings are: 1 - Buy stocks are expected to have a total return of at least 10% and are the most attractive stocks in the coverage cluster; 2 - Neutral stocks are expected to remain flat or increase in value and are less attractive than Buy rated stocks and 3 - Underperformstocks are the least attractive stocks in a coverage cluster. An investment rating of 6 (No Rating) indicates that a stock is no longer trading on the basis of fundamentals. Analysts assign investment ratings considering, among other things, the 0-12 month total return expectation for a stock and the firm's guidelines for ratings dispersions (shown in the table below). The current price objective for a stock should be referenced to better understand the total return expectation at any given time. The price objective reflects the analyst's view of the potential price appreciation (depreciation).

Investment rating	Total return expectation (within 12-month period of date of initial rating)	Ratings dispersion guidelines for coverage cluster <sup>R1</sup>
Buv	≥ 10%	≤ 70%

Buy≥ 10%≤ 70%Neutral≥ 0%≤ 30%UnderperformN/A≥ 20%

INCOME RATINGS, indicators of potential cash dividends, are: 7 - same/higher (dividend considered to be secure), 8 - same/lower (dividend not considered to be secure) and 9 - pays no cash dividend. Coverage Cluster is comprised of stocks covered by a single analyst or two or more analysts sharing a common industry, sector, region or other classification(s). A stock's coverage cluster is included in the most recent BofA Global Research report referencing the stock.

## Other Important Disclosures

Prices are indicative and for information purposes only. Except as otherwise stated in the report, for any recommendation in relation to an equity security, the price referenced is the publicly traded price of the security as of close of business on the day prior to the date of the report or, if the report is published during intraday trading, the price referenced is indicative of the traded price as of the date and time of the report and in relation to a debt security (including equity preferred and CDS), prices are indicative as of the date and time of the report and are from various sources including BofA Securities trading desks.

The date and time of completion of the production of any recommendation in this report shall be the date and time of dissemination of this report as recorded in the report timestamp.

"BofA Securities" includes BofA Securities, Inc. ("BofAS") and its affiliates. Investors should contact their BofA Securities representative or Merrill Global Wealth Management financial advisor if they have questions concerning this report or concerning the appropriateness of any investment idea described herein for such investor. "BofA Securities" is a global brand for BofA Global Research.

Information relating to Non-US affiliates of BofA Securities and Distribution of Affiliate Information:

BofAS and/or Merrill Lynch, Pierce, Fenner & Smith Incorporated ("MLPF&S") may in the future distribute, information of the following non-US affiliates in the US (short name: legal name, regulator): Merrill Lynch (South Africa): Merrill Lynch South Africa (Pty) Ltd., regulated by The Financial Service Board; MLI (UK): Merrill Lynch International, regulated by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA); BofASE (France): BofA Securities Europe SA is authorized by the Autorité de Contrôle Prudential et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers (AMF). BofA Securities Europe SA ("BofASE") with registered address at 51, rue La Boétie, 75008 Paris is registered under no 842 602 690 RCS Paris. In accordance with the provisions of French Code Monétaire et Financier (Monetary and Financial Code), BofASE is an établissement de crédit et d'investissement (credit and investment institution) that is authorised and supervised by the European Central Bank and the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and regulated by the ACPR and the Autorité des Marchés Financiers. BofASE's share capital can be found at www.bofaml.com/BofASEdisclaimer; BofA Europe (Milan): Bank of America Europe Designated Activity Company, Milan Branch, regulated by the Bank of Italy, the European Central Bank (ECB) and the Central Bank of Ireland (CBI), BofA Europe (Frankfurt): Bank of America Europe Designated Activity Company, Frankfurt Branch regulated by BaFin, the ECB and the CBI; BofA Europe (Madrid): Bank of America Europe Designated Activity Company, Sucursal en España, regulated by the Bank of Spain, the ECB and the CBI; Merrill Lynch (Australia): Merrill Lynch Equities (Australia) Limited, regulated by the Australian Securities and Investments Commission; Merrill Lynch (Hong Kong): Merrill Lynch (Asia Pacific) Limited, regulated by the Hong Kong Securities and Futures Commission (HKSFC); Merrill Lynch (Singapore): Merrill Lynch (Singapore) Pte Ltd, regulated by the Monetary Authority of Singapore (MAS); Merrill Lynch (Canada): Merrill Lynch Canada Inc, regulated by the Canadian Investment Regulatory Organization; Merrill Lynch (Mexico): Merrill Lynch Mexico, SA de CV, Casa de Bolsa, regulated by the Comisión Nacional Bancaria y de Valores; Merrill Lynch (Argentina): Merrill Lynch Argentina SA, regulated by Comisión Nacional de Valores; BofAS Japan: BofA Securities Japan Co., Ltd., regulated by the Financial Services Agency; Merrill Lynch (Seoul): Merrill Lynch International, LLC Seoul Branch, regulated by the Financial Supervisory Service; Merrill Lynch (Taiwan): Merrill Lynch Securities (Taiwan) Ltd., regulated by the Securities and Futures Bureau; BofAS India: BofA Securities India Limited, regulated by the Securities and Exchange Board of India (SEBI); Merrill Lynch (Israel): Merrill Lynch Israel Limited, regulated by Israel Securities Authority; Merrill Lynch (DIFC): Merrill Lynch International (DIFC Branch), regulated by the Dubai Financial Services Authority (DFSA); Merrill Lynch (Brazil): Merrill Lynch S.A. Corretora de Títulos e Valores Mobiliários, regulated by Comissão de Valores Mobiliários; Merrill Lynch KSA Company: Merrill Lynch Kingdom of Saudi Arabia Company, regulated by the Capital Market Authority.

This information: has been approved for publication and is distributed in the United Kingdom (UK) to professional clients and eligible counterparties (as each is defined in the rules of the FCA and the PRA) by MLI (UK), which is authorized by the PRA and regulated by the FCA and the PRA - details about the extent of our regulation by the FCA and PRA are available from us on request; has been approved for publication and is distributed in the European Economic Area (EEA) by BofASE (France), which is authorized by the ACPR and regulated by the ACPR and the AMF; has been considered and distributed in Japan by BofAS Japan, a registered securities dealer under the Financial Instruments and Exchange Act in Japan, or its permitted affiliates; is issued and distributed in Hong Kong by Merrill Lynch (Hong Kong) which is regulated by HKSFC; is issued and distributed in Taiwan by Merrill Lynch (Taiwan); is issued and distributed in India by BofAS India; and is issued and distributed in Singapore to institutional investors and/or accredited investors (each as defined under the Financial Advisers Regulations) by Merrill Lynch (Singapore) (Company Registration No 198602883D). Merrill Lynch (Singapore) is regulated by MAS. Merrill Lynch Equities (Australia) Limited (ABN 65 006 276 795), AFS License 235132 (MLEA) distributes this information in Australia only to "Wholesale' clients as defined by s.761G of the Corporations Act 2001. With the exception of Bank of America N.A., Australia Branch, neither MLEA nor any of its affiliates involved in preparing this information is an Authorised Deposit-Taking Institution under the Banking Act 1959 nor regulated by the Australian Prudential Regulation Authority. No approval is required for publication or distribution of this information in Brazil and its local distribution is by Merrill Lynch (Brazil) in accordance with applicable regulations. Merrill Lynch (DIFC) is authorized and regulated by the DFSA. Information in Germany and is regulated by BaFin, the ECB and the CBI. BofA Securit

This information has been prepared and issued by BofAS and/or one or more of its non-US affiliates. The author(s) of this information may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so. BofAS and/or MLPF&S is the distributor of this information in the US and accepts full responsibility for information distributed to BofAS and/or MLPF&S clients in the US by its non-US affiliates. Any US person receiving this information and wishing to effect any transaction in any security



Ratings dispersions may vary from time to time where BofA Global Research believes it better reflects the investment prospects of stocks in a Coverage Cluster.

discussed herein should do so through BofAS and/or MLPF&S and not such foreign affiliates. Hong Kong recipients of this information should contact Merrill Lynch (Asia Pacific) Limited in respect of any matters relating to dealing in securities or provision of specific advice on securities or any other matters arising from, or in connection with, this information. Singapore recipients of this information should contact Merrill Lynch (Singapore) Pte Ltd in respect of any matters arising from, or in connection with, this information. For clients that are not accredited investors, expert investors or institutional investors Merrill Lynch (Singapore) Pte Ltd accepts full responsibility for the contents of this information distributed to such clients in Singapore.

#### General Investment Related Disclosures:

Taiwan Readers: Neither the information nor any opinion expressed herein constitutes an offer or a solicitation of an offer to transact in any securities or other financial instrument. No part of this report may be used or reproduced or quoted in any manner whatsoever in Taiwan by the press or any other person without the express written consent of BofA Securities. This document provides general information only, and has been prepared for, and is intended for general distribution to, BofA Securities clients. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other financial instrument or any derivative related to such securities or instruments (e.g., options, futures, warrants, and contracts for differences). This document is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of, and is not directed to, any specific person(s). This document and its content do not constitute, and should not be considered to constitute, investment advice for purposes of ERISA, the US tax code, the Investment Advisers Act or otherwise. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Any decision to purchase or subscribe for securities in any offering must be based solely on existing public information on such security or the information in the prospectus or other offering document issued in connection with such offering, and not on this document.

Securities and other financial instruments referred to herein, or recommended, offered or sold by BofA Securities, are not insured by the Federal Deposit Insurance Corporation and are not deposits or other obligations of any insured depository institution (including, Bank of America, N.A.). Investments in general and, derivatives, in particular, involve numerous risks, including, among others, market risk, counterparty default risk and liquidity risk. No security, financial instrument or derivative is suitable for all investors. Digital assets are extremely speculative, volatile and are largely unregulated. In some cases, securities and other financial instruments may be difficult to value or sell and reliable information about the value or risks related to the security or financial instrument may be difficult to obtain. Investors should note that income from such securities and other financial instruments, if any, may fluctuate and that price or value of such securities and instruments may rise or fall and, in some cases, investors may lose their entire principal investment. Past performance is not necessarily a guide to future performance. Levels and basis for taxation may change.

BofA Securities, through business units other than BofA Global Research, may have issued and may in the future issue trading ideas or recommendations that are inconsistent with, and reach different conclusions from, the information presented herein. Such ideas or recommendations may reflect different time frames, assumptions, views and analytical methods of the persons who prepared them, and BofA Securities is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this information. In the event that the recipient received this information pursuant to a contract between the recipient and BofAS for the provision of research services for a separate fee, and in connection therewith BofAS may be deemed to be acting as an investment adviser, such status relates, if at all, solely to the person with whom BofAS has contracted directly and does not extend beyond the delivery of this report (unless otherwise agreed specifically in writing by BofAS). If such recipient uses the services of BofAS in connection with the sale or purchase of a security referred to herein, BofAS may act as principal for its own account or as agent for another person. BofAS is and continues to act solely as a broker-dealer in connection with the execution of any transactions, including transactions in any securities referred to herein.

## Copyright and General Information:

Copyright 2024 Bank of America Corporation. All rights reserved. iQdatabase® is a registered service mark of Bank of America Corporation. This information is prepared for the use of BofA Securities clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of BofA Securities. BofA Global Research information is distributed simultaneously to internal and client websites and other portals by BofA Securities and is not publicly-available material. Any unauthorized use or disclosure is prohibited. Receipt and review of this information constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained herein (including any investment recommendations, estimates or price targets) without first obtaining express permission from an authorized officer of BofA Securities. Materials prepared by BofA Global Research personnel are based on public information. Facts and views presented in this material have not been reviewed by, and may not reflect information known to, professionals in other business areas of BofA Securities, including investment banking personnel. BofA Securities has established information barriers between BofA Global Research and certain business groups. As a result, BofA Securities does not disclose certain client relationships with, or compensation received from, such issuers. To the extent this material discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this material. BofA Global Research personnel's knowledge of legal proceedings in which any BofA Securities entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving issuers mentioned in this material is based on public inform

This information has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities. None of BofAS any of its affiliates or their research analysts has any authority whatsoever to make any representation or warranty on behalf of the issuer(s). BofA Global Research policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer prior to the publication of a research report containing such rating, recommendation or investment thesis.

The information herein (other than disclosure information relating to BofA Securities and its affiliates) was obtained from various sources and we do not guarantee its accuracy. This information may contain links to third-party websites. BofA Securities is not responsible for the content of any third-party website or any linked content contained in a third-party website. Content contained on such third-party websites is not part of this information and is not incorporated by reference. The inclusion of a link does not imply any endorsement by or any affiliation with BofA Securities. Access to any third-party website is at your own risk, and you should always review the terms and privacy policies at third-party websites before submitting any personal information to them. BofA Securities is not responsible for such terms and privacy policies and expressly disclaims any liability for them.

All opinions, projections and estimates constitute the judgment of the author as of the date of publication and are subject to change without notice. Prices also are subject to change without notice. BofA Securities is under no obligation to update this information and BofA Securities ability to publish information on the subject issuer(s) in the future is subject to applicable quiet periods. You should therefore assume that BofA Securities will not update any fact, circumstance or opinion contained herein.

Certain outstanding reports or investment opinions relating to securities, financial instruments and/or issuers may no longer be current. Always refer to the most recent research report relating to an issuer prior to making an investment decision.

In some cases, an issuer may be classified as Restricted or may be Under Review or Extended Review. In each case, investors should consider any investment opinion relating to such issuer (or its security and/or financial instruments) to be suspended or withdrawn and should not rely on the analyses and investment opinion(s) pertaining to such issuer (or its securities and/or financial instruments) nor should the analyses or opinion(s) be considered a solicitation of any kind. Sales persons and financial advisors affiliated with BofAS or any of its affiliates may not solicit purchases of securities or financial instruments that are Restricted or Under Review and may only solicit securities under Extended Review in accordance with firm policies.

Neither BofA Securities nor any officer or employee of BofA Securities accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this information.

